Antibodies against SARS-CoV-2 Time Course in Patients and Vaccinated Subjects: An Evaluation of the Harmonization of Two Different Methods
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
The time course of antibodies against SARS-CoV-2 is not yet well elucidated, especially in people who underwent a vaccination campaign. In this study, we measured the antibodies anti-S1 and anti-RBD with two different methods, both in patients and in vaccinated subjects. One hundred and eight specimens from 48 patients with COVID-19 (time from the onset of symptoms from 3 to 368 days) and 60 specimens from 20 vaccinated subjects (collected after 14 days from the first dose, 14 days and 3 months after a second dose of Comirnaty) were evaluated. We used an ELISA method that measured IgG against anti-Spike 1, and a chemiluminescence immunoassay that measured IgG anti-RBD. In the patients, the antibodies concentrations tended to decline after a few months, with both the methods, but they persisted relatively high up to nearly a year after the symptoms. In the vaccinated subjects, the antibodies were already detectable after the first dose, but after the booster, they showed a significant increase. However, the decrease was rapid, given that 3 months after the second vaccination, they were reduced to less than a quarter. The conversion of the results into BAU units improves the relationship between the two methods. However, in the vaccinated subjects, there was no evidence of proportional error after the conversion, while in the patients, the difference between the two methods remained significant.
Article activity feed
-
-
SciScore for 10.1101/2021.08.28.21262543: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable Forty-eight patients with known date of symptoms’ onset were included in the study (41 males, 7 females, median age 62.3 years, minimum 28, maximum 87). Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources The IgG anti-RBD method measure antibodies against receptor binding domain of the S1 protein, were carried out on the analyser Maglumi 800 (SNIBE, Shenzen, China), and use a nine-point master curve (from 1 to 100 Arbitrary Units/mL) periodically adjusted by a 2-point calibration. anti-RBD method measure antibodies against receptor binding domainsuggested: NoneSoftware and Algorithms Se… SciScore for 10.1101/2021.08.28.21262543: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable Forty-eight patients with known date of symptoms’ onset were included in the study (41 males, 7 females, median age 62.3 years, minimum 28, maximum 87). Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources The IgG anti-RBD method measure antibodies against receptor binding domain of the S1 protein, were carried out on the analyser Maglumi 800 (SNIBE, Shenzen, China), and use a nine-point master curve (from 1 to 100 Arbitrary Units/mL) periodically adjusted by a 2-point calibration. anti-RBD method measure antibodies against receptor binding domainsuggested: NoneSoftware and Algorithms Sentences Resources The statistical analyses were performed with MedCalc © Software, Version 7.4.2.0 (MedCalc Software, Mariakerke, Belgium). MedCalcsuggested: (MedCalc, RRID:SCR_015044)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
